Vifor Pharma

Vifor Pharma EBIT

Delisted·Dec 22, 2022

The EBIT of Vifor Pharma (VIFN.SW) as of Nov 7, 2026 is 422.30 M CHF. In the previous year, EBIT was 266.60 M CHF — a change of 58.40% (higher).

EBIT

422.30 MCHF

YoY

58.40%

Last updated:

In 2021, Vifor Pharma's EBIT was 422.30 M CHF, a 58.40% increase from the 266.60 M CHF EBIT recorded in the previous year.

The Vifor Pharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2019
325.00 M CHF
Jan 1, 2020
266.60 M CHF
Jan 1, 2021
422.30 M CHF
Jan 1, 2022 (e)
408.00 M CHF
Jan 1, 2023 (e)
468.18 M CHF
Jan 1, 2024 (e)
543.66 M CHF
Jan 1, 2025 (e)
801.47 M CHF
Jan 1, 2026 (e)
948.40 M CHF
The Vifor Pharma EBIT history
YEAREBITYoY
est948.40 MCHF+18.33%
est801.47 MCHF+47.42%
est543.66 MCHF+16.12%
est468.18 MCHF+14.75%
est408.00 MCHF-3.39%
422.30 MCHF+58.40%
266.60 MCHF-17.97%
325.00 MCHF+76.44%
184.20 MCHF+37.16%
134.30 MCHF-62.30%
356.24 MCHF-20.10%
445.84 MCHF+23.53%
360.92 MCHF-5.90%
383.56 MCHF+13.70%
337.34 MCHF+3.12%
327.13 MCHF+0.72%
324.80 MCHF-48.77%
633.96 MCHF-7.81%
687.69 MCHF+361.26%
149.09 MCHF+39.93%
106.55 MCHF+9.92%
96.93 MCHF+20.61%
80.37 MCHF-29.84%
114.56 MCHF-13.78%
132.87 MCHF—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vifor Pharma Revenue

Vifor Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
1.88 B CHF
325.00 M CHF
159.10 M CHF
Jan 1, 2020
1.71 B CHF
266.60 M CHF
359.60 M CHF
Jan 1, 2021
1.82 B CHF
422.30 M CHF
144.40 M CHF
Jan 1, 2022 (e)
1.86 B CHF
408.00 M CHF
235.56 M CHF
Jan 1, 2023 (e)
2.08 B CHF
468.18 M CHF
275.14 M CHF
Jan 1, 2024 (e)
2.42 B CHF
543.66 M CHF
326.31 M CHF
Jan 1, 2025 (e)
2.71 B CHF
801.47 M CHF
583.34 M CHF
Jan 1, 2026 (e)
3.00 B CHF
948.40 M CHF
692.86 M CHF

Vifor Pharma Margins

Vifor Pharma stock margins

The Vifor Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vifor Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vifor Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
59.44 %
17.31 %
8.47 %
Jan 1, 2020
58.89 %
15.63 %
21.08 %
Jan 1, 2021
63.18 %
23.14 %
7.91 %
Jan 1, 2022 (e)
63.18 %
21.91 %
12.65 %
Jan 1, 2023 (e)
63.18 %
22.53 %
13.24 %
Jan 1, 2024 (e)
63.18 %
22.43 %
13.46 %
Jan 1, 2025 (e)
63.18 %
29.56 %
21.51 %
Jan 1, 2026 (e)
63.18 %
31.63 %
23.11 %

Vifor Pharma Stock analysis

What does Vifor Pharma do? Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Vifor Pharma's EBIT

Vifor Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Vifor Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Vifor Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Vifor Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Vifor Pharma stock

EBIT of Vifor Pharma is 422.30 M CHF in 2021.

EBIT of Vifor Pharma changed from 266.60 M CHF to 422.30 M CHF, representing a 58.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Vifor Pharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CHF is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Vifor Pharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Vifor Pharma

All Key Metrics — Vifor Pharma